(RTTNews) - While reporting financial results for the fourth quarter on Thursday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) provided earnings, adjusted earnings and revenue guidance for the full-year 2023.
For fiscal 2023, the company now projects earnings in a range of $4.03 to $4.33 per share and adjusted earnings of $7.95 to $8.25 per share on worldwide total revenue growth of about 2 percent.
On average, 21 analysts polled by Thomson Reuters expect the company to report earnings of $8.0 per share on revenues growth of 2.7 percent to $47.15 billion for the year. Analysts' estimates typically exclude special items.
For the fourth quarter, the company reported net income attributable to Bristol-Myers Squibb of $2.02 billion or $0.95 per share, down from $2.37 billion or $1.07 per share in the prior-year quarter. Excluding items, adjusted net earnings per share for the quarter was $1.82, compared to last year's $1.84.
Total revenues for the quarter declined 5 percent to $11.41 billion from $11.99 billion in the same quarter last year.
Analysts expected quarterly earnings of $1.72 per share on revenues of $11.20 billion for the quarter.
U.S. revenues increased 5 percent to $7.9 billion, while international revenues decreased 22 percent to $3.5 billion from last year.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.